AIM: To study the levels of serum soluble intercellular adhesion molecule-1 (sICAM-1), plasma D-lactate and diamine oxidase (DAO) in patients with inflammatory bowel disease (IBD), and the potential clinical significance. METHODS: Sixty-nine patients with IBD and 30 healthy controls were included in this study. The concentration of sICAM-1 was detected with enzyme-linked immunosorbent assay, the level of D-lactate and DAO was measured by spectroscopic analysis, and the number of white blood cells (WBC) was determined by routine procedure. RESULTS: The levels of sICAM-l, DAO, and WBC in IBD patients were significantly higher than those in the control group (P < 0.01). sICAM-l in IBD patients was found to be closely related to the levels of DAO and D-lactate (212.94 +/- 69.89 vs 6.35 +/- 2.35, P = 0.000), DAO 212.94 +/- 69.89 vs 8.65 +/- 3.54, P = 0.000) and WBC (212.94 +/- 69.89 vs 7.40 +/- 2.61, P = 0.000), but no significant difference was observed between patients with ulcerative colitis and patients with Crohn's disease. The post-treatment levels of sICAM-l, D-lactate and WBC were significantly lower than before treatment (sICAM-l 206.57 +/- 79.21 vs 146.21 +/- 64.43, P = 0.000), (D-lactate 1.46 +/- 0.94 vs 0.52 +/- 0.32, P = 0.000) and (WBC 7.24 +/- 0.2.33 vs 5.21 +/- 3.21, P = 0.000). CONCLUSION: sICAM-1, D-lactate and DAO are closely related to the specific conditions of IBD, and thus could be used as a major diagnostic index.
AIM: To study the levels of serum soluble intercellular adhesion molecule-1 (sICAM-1), plasma D-lactate and diamine oxidase (DAO) in patients with inflammatory bowel disease (IBD), and the potential clinical significance. METHODS: Sixty-nine patients with IBD and 30 healthy controls were included in this study. The concentration of sICAM-1 was detected with enzyme-linked immunosorbent assay, the level of D-lactate and DAO was measured by spectroscopic analysis, and the number of white blood cells (WBC) was determined by routine procedure. RESULTS: The levels of sICAM-l, DAO, and WBC in IBD patients were significantly higher than those in the control group (P < 0.01). sICAM-l in IBD patients was found to be closely related to the levels of DAO and D-lactate (212.94 +/- 69.89 vs 6.35 +/- 2.35, P = 0.000), DAO 212.94 +/- 69.89 vs 8.65 +/- 3.54, P = 0.000) and WBC (212.94 +/- 69.89 vs 7.40 +/- 2.61, P = 0.000), but no significant difference was observed between patients with ulcerative colitis and patients with Crohn's disease. The post-treatment levels of sICAM-l, D-lactate and WBC were significantly lower than before treatment (sICAM-l 206.57 +/- 79.21 vs 146.21 +/- 64.43, P = 0.000), (D-lactate 1.46 +/- 0.94 vs 0.52 +/- 0.32, P = 0.000) and (WBC 7.24 +/- 0.2.33 vs 5.21 +/- 3.21, P = 0.000). CONCLUSION: sICAM-1, D-lactate and DAO are closely related to the specific conditions of IBD, and thus could be used as a major diagnostic index.
Authors: B E Theien; C L Vanderlugt; T N Eagar; C Nickerson-Nutter; R Nazareno; V K Kuchroo; S D Miller Journal: J Clin Invest Date: 2001-04 Impact factor: 14.808
Authors: William J Mack; J Mocco; Daniel J Hoh; Judy Huang; Tanvir F Choudhri; Kurt T Kreiter; Alan Lozier; Marcello Opperman; Alexander Poisik; Joshua Yorgason; Robert A Solomon; Stephan A Mayer; E Sander Connolly Journal: J Neurosurg Date: 2002-01 Impact factor: 5.115
Authors: P Suenaert; V Bulteel; E Den Hond; B Geypens; F Monsuur; A Luypaerts; Y Ghoos; P Rutgeerts Journal: Scand J Gastroenterol Date: 2003-04 Impact factor: 2.423
Authors: T Taniguchi; H Tsukada; H Nakamura; M Kodama; K Fukuda; T Saito; M Miyasaka; Y Seino Journal: J Gastroenterol Hepatol Date: 1998-09 Impact factor: 4.029
Authors: Tao Sun; Guang-Zhou Gao; Rong-Fu Li; Xin Li; Da-Wei Li; Shan-Shan Wu; Anthony Et Yeo; Bo Jin Journal: Am J Transl Res Date: 2015-05-15 Impact factor: 4.060
Authors: H T Yu; X L Ding; N Li; X Y Zhang; X F Zeng; S Wang; H B Liu; Y M Wang; H M Jia; S Y Qiao Journal: J Anim Sci Date: 2017-11 Impact factor: 3.159
Authors: Jean L J M Scheijen; Nordin M J Hanssen; Marjo P H van de Waarenburg; Daisy M A E Jonkers; Coen D A Stehouwer; Casper G Schalkwijk Journal: Exp Diabetes Res Date: 2012-03-08